⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Surveillance AFter Extremity Tumor surgerY

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Surveillance AFter Extremity Tumor surgerY

Official Title: Surveillance AFter Extremity Tumor surgerY (SAFETY) International Randomized Controlled Trial

Study ID: NCT03944798

Study Description

Brief Summary: Following treatment for a primary extremity sarcoma, patients remain at risk for the development of local and systemic disease recurrence. Metastasis (distant recurrence) to the lung is the most frequent single location of disease recurrence in sarcoma patients, occurring in almost half of all patients. Therefore, careful post-operative surveillance is an integral element of patient care. However, the detection of metastases does not necessarily affect long-term survival and may negatively impact quality of life. Surveillance strategies have not been well researched and have been identified as the top research priority in the extremity sarcoma field. Using a 2X2 factorial design to maximize efficiency and reduce overall trial costs, the SAFETY trial will randomize 830 extremity soft-tissue sarcoma (STS) patients to determine the effect of surveillance strategy on overall patient survival after surgery for a STS of the extremity by comparing the effectiveness of both surveillance frequency (every 3 vs. every 6 months) and imaging modality (CT scans vs. chest radiographs).

Detailed Description: Post-treatment STS surveillance is an integral element of patient care. Although earlier detection of metastatic disease may improve long-term survival, no study has yet provided definitive evidence to support this assumption. A thorough systematic review of the literature has identified only a single limited randomized controlled trial (RCT) evaluating this clinical question, and surveys of sarcoma surgeons have determined that surgeons typically follow their patients based on the way in which they were trained. The orthopaedic oncology field has identified sarcoma surveillance strategy as the top research priority in the field. In order to fill the evidence gap in sarcoma surveillance, a large international RCT is required. The investigators, therefore, propose the Surveillance AFter Extremity Tumor surgerY (SAFETY) trial. In preparation for the SAFETY trial, the SAFETY investigators have completed the following preparatory work: A) establishment of a worldwide research collaborative group that spans 6 continents; B) collection of data from international sarcoma patients to determine their perceptions of sarcoma surveillance and their willingness to participate in a study in which randomization will determine their follow-up protocols; and C) the organization of a large Protocol Development Meeting with international and multidisciplinary participation, including sarcoma patient involvement, where critical aspects of the protocol were discussed and finalized. The international, multi-center SAFETY trial will determine the effect of surveillance strategy on overall patient survival after surgery for a STS of the extremity by comparing the effectiveness of both surveillance frequency (every 3 vs. every 6 months) and imaging modality (CT scans vs. chest radiographs). Ultimately, the SAFETY trial will provide the necessary evidence to develop evidence-based surveillance guidelines, and is poised to have a significant impact on the post-operative care and outcomes of extremity soft-tissue sarcoma patients.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University of California Davis Medical Center, Sacramento, California, United States

Hartford HealthCare, Hartford, Connecticut, United States

University of Florida Health Shands Hospital, Gainesville, Florida, United States

Parkview Cancer Institute, Fort Wayne, Indiana, United States

Holden Comprehensive Cancer Center, Iowa City, Iowa, United States

Albany Medical Center, Albany, New York, United States

Montefiore Medical Center, Bronx, New York, United States

NYU Langone Orthopaedic Hospital/Perlmutter Cancer Center, New York, New York, United States

Cleveland Clinic, Cleveland, Ohio, United States

Oregon Health and Science University Hospital, Portland, Oregon, United States

Texas Tech Health Sciences Center, El Paso, Texas, United States

Huntsman Cancer Institute, Salt Lake City, Utah, United States

Virginia Cancer Specialists, Fairfax, Virginia, United States

Hospital Universitario Austral, Buenos Aires, , Argentina

St. Vincent's Hospital Melbourne, Fitzroy, Melbourne, Australia

LKH - Universitätsklinikum Graz, Graz, , Austria

Hospital de Clínicas de Porto Alegre, Porto Alegre, , Brazil

Nova Scotia Health, Halifax, Nova Scotia, Canada

Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada

The Ottawa Hospital, Ottawa, Ontario, Canada

Mount Sinai Hospital, Toronto, Ontario, Canada

Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada

McGill University Health Centre, Montréal, Quebec, Canada

Hôtel Dieu du Quebec, Québec, Quebec, Canada

Centro Traumatologico Ortopedico Hospital, Turin, , Italy

Leiden University Medical Center, Leiden, , Netherlands

Contact Details

Name: Michelle Ghert, MD, FRCSC

Affiliation: McMaster University

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: